论文部分内容阅读
AIM:To investigate the correlation between human epidermal growth factor receptor(HER-2) protein expression and colorectal cancer(CRC) using a casecontrol study and meta-analysis.METHODS:Tumor tissue specimens from 162 CRC patients were selected for the case group.Fifty cases were randomly selected,and normal CRC tissue at least 10 cm away from the tumor margins of these cases was used to generate the control group.The expression of the HER-2 protein in the 162 CRC tissue samples and the 50 adjacent normal mucosa tissue samples was detected via immunohistochemistry.The experimental data were analyzed using SPSS 18.0software,and R software version 3.1.0 was utilized for further verification.RESULTS:The expression of HER-2 protein in the 162 CRC tissue samples was significantly higher than in the normal tissue specimens.The data showed that the expression of HER-2 in CRC was related to the Dukes’ stage,the depth of invasion and lymph node metastasis.The HER-2-positive patients had lower 3-and 5-year OS rates than the HER-2-negative patients,but there was no significant difference.However,there was a statistically significant difference in the 3- and5-year disease-free survival(DFS) rates of HER-2-positive and HER-2-negative patients.The results of the meta-analysis showed that the expression of HER-2in CRC patients was statistically significantly increased over that of healthy people.The 3-year DFS rate in HER-2-positive patients was markedly lower than that in HER-2-negative patients.CONCLUSION:Down-regulation of HER-2 expression might be a dependable strategy for CRC therapy.
AIM: To investigate the correlation between human epidermal growth factor receptor (HER-2) protein expression and colorectal cancer (CRC) using a case control study and meta-analysis. METHODS: Tumor tissue specimens from 162 CRC patients were selected for the case group. Fifty cases were randomly selected, and normal CRC tissue at least 10 cm away from the tumor margins of these cases was used to generate the control group. The expression of the HER-2 protein in the 162 tissue samples and the 50 adjacent normal mucosa tissue samples was detected via immunohistochemistry. The experimental data were analyzed using SPSS 18.0 software, and R software version 3.1.0 was utilized for further verification.RESULTS: The expression of HER-2 protein in the 162 CRC tissue samples was significantly higher than in the normal tissue specimens. the data showed that the expression of HER-2 in CRC was related to the Dukes’ stage, the depth of invasion and lymph node metastasis. HER-2-positive patients had lower 3-and 5-year OS rates than the HER-2-negative patients, but there was no significant difference. However, there was a significant difference in the 3- and 5-year disease-free survival (DFS) rates of HER- 2-positive and HER-2-negative patients.The results of the meta-analysis showed that the expression of HER-2 in CRC patients was judiciously increased over that of healthy people.The 3-year DFS rate in HER-2-positive patients was markedly lower than that in HER-2-negative patients. CONCLUSION: Down-regulation of HER-2 expression might be a dependable strategy for CRC therapy.